Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
66 hedge funds and large institutions have $430M invested in Day One Biopharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
14% more funds holding
Funds holding: 58 → 66 (+8)
2.92% more ownership
Funds ownership: 66.97% → 69.9% (+2.9%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
38% less capital invested
Capital invested by funds: $698M → $430M (-$269M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$7.68M |
| 3 |
BlackRock
New York
|
+$5.43M |
| 4 |
Millennium Management
New York
|
+$2.31M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.44M |
| 2 |
PCM
Pathway Capital Management
Irvine,
California
|
-$4.08M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.12M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$1.59M |
| 5 |
DM
Deerfield Management
New York
|
-$1.53M |
DAWN Hedge Fund Activity: Q1 2022 in Review
66 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2022, worth a combined $430M — down 38% from $698M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DAWN positions and 10 closed out — a net gain of 8 holders — while 21 added to existing stakes and 12 trimmed.
The largest buyer was RA Capital Management, adding an estimated $14.5M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $6.44M sold.
- 66 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2022, up from 58 in Q4 2021.
- Funds reported $430M of Day One Biopharmaceuticals stock for Q1 2022, down 38% quarter-over-quarter.
- 18 funds opened new Day One Biopharmaceuticals positions in Q1 2022 and 10 closed out, a net change of +8 holders.
- The largest Day One Biopharmaceuticals buyer in Q1 2022 was RA Capital Management, an estimated $14.5M added.
- The largest Day One Biopharmaceuticals seller in Q1 2022 was Rock Springs Capital Management, an estimated $6.44M sold.
Based on aggregated 13F filings for Q1 2022.